Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute kidney injury
Biotech
Dimerix buys Mission’s kidney disease prospect in $292M deal
Dimerix is Mission paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready acute kidney injury asset.
Nick Paul Taylor
Jul 17, 2026 5:00am
Genentech shreds RIPK1 inhibitor after ph. 2 failure
Mar 19, 2026 2:48pm
CalciMedica stock craters as trial stopped over 'safety concern'
Jan 28, 2026 8:40am
Kidney monitor maker Potrero Medical files for bankruptcy
Dec 1, 2023 4:40pm
AM-Pharma cuts staff, CEO leaves as lead asset redirected
Sep 26, 2023 10:39am
Guard argues new data render primary endpoint miss 'irrelevant'
Sep 19, 2023 9:35am
